Immune checkpoint inhibitors (ICI) myopathy
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Immune checkpoint inhibitors (ICI) myopathy. Nivolumab, Pembrolizumab, Ipilimumab, Durvalumab, Atezolizumab. Fully referenced neurology checklist.
Causes
- Nivolumab
- Pembrolizumab
- Ipilimumab
- Durvalumab
- Atezolizumab
Onset features
Locked: subscribe to see this section.
Clinical features
Locked: subscribe to see this section.
Overlap features
Locked: subscribe to see this section.
Differential diagnosis
Locked: subscribe to see this section.
Investigations
Locked: subscribe to see this section.
Prognosis
Locked: subscribe to see this section.
Treatment
Locked: subscribe to see this section.
References
- Touat M, Maisonobe T, Knauss S, et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology 2018; 91:e985-e994.
- Shah M, Tayar JH, Abdel-Wahab N, Suarez-Almazor ME. Myositis as an adverse event of immune checkpoint blockade for cancer therapy. Semin Arthritis Rheum 2019; 48:736-740.
- Beecher G, Pinal-Fernandez I, Mammen AL, Liewluck T. Immune checkpoint inhibitor myopathy: the double-edged sword of cancer immunotherapy. Neurology 2024; 103:e210031.
- Moreira A, Loquai C, Pföhler C, et al. Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur J Cancer 2019; 106:12-23.
- Uchio N, Taira K, Ikenaga C, et al. Inflammatory myopathy with myasthenia gravis: thymoma association and polymyositis pathology. Neurol Neuroimmunol Neuroinflamm 2018; 6:e535.
- And 1 more. Subscribe to see the full list
